VEGFA and neoplasm: As everolimus can reduce VEGF-A production, it was evaluated whether NET lesions can be visualized by 89Zr-bevacizumab PET and whether tumor uptake of 89Zr-bevacizumab decreases from baseline to week 2 and 12 during everolimus therapy (10 mg orally once daily).